Institute of Pharmaceutical Chemistry, Faculty of Pharmacy, Philipps-University Marburg, Marburg, Germany.
Oncogene. 2012 Feb 16;31(7):918-28. doi: 10.1038/onc.2011.278. Epub 2011 Jul 11.
The constitutively active serine/threonine kinase Pim-1 is upregulated in different cancer types, mainly based on the action of several interleukines and growth factors at the transcriptional level. So far, a regulation of oncogenic Pim-1 by microRNAs (miRNAs) has not been reported. Here, we newly establish miR-33a as a miRNA with potential tumor suppressor activity, acting through inhibition of Pim-1. A screen for miRNA expression in K562 lymphoma, LS174T colon carcinoma and several other cell lines revealed generally low endogenous miR-33a levels relative to other miRNAs. Transfection of K562 and LS174T cells with a miR-33a mimic reduced Pim-1 levels substantially. In contrast, the cell-cycle regulator cyclin-dependent kinase 6 predicted to be a conserved miR-33a target, was not downregulated by the miR-33a mimic. Seed mutagenesis of the Pim-1 3'-untranslated region in a luciferase reporter construct and in a Pim-1 cDNA expressed in Pim-1-deficient Skov-3 cells demonstrated specific and direct downregulation of Pim-1 by the miR-33a mimic. The persistence of this effect was comparable to that of a small interfering RNA-mediated knockdown of Pim-1, resulting in decelerated cell proliferation. In conclusion, we demonstrate the potential of miR-33a to act as a tumor suppressor miRNA, which suggests miR-33a replacement therapy through delivery of miR mimics as a novel therapeutic strategy.
组成性激活的丝氨酸/苏氨酸激酶 Pim-1 在不同类型的癌症中上调,主要基于几种白细胞介素和生长因子在转录水平上的作用。到目前为止,还没有报道过 microRNAs(miRNAs)对致癌 Pim-1 的调节。在这里,我们新确定 miR-33a 是一种具有潜在肿瘤抑制活性的 miRNA,通过抑制 Pim-1 发挥作用。对 K562 淋巴瘤、LS174T 结肠癌细胞和其他几种细胞系中的 miRNA 表达进行筛选,结果显示内源性 miR-33a 水平相对其他 miRNA 普遍较低。用 miR-33a 模拟物转染 K562 和 LS174T 细胞可显著降低 Pim-1 水平。相比之下,细胞周期调节因子 cyclin-dependent kinase 6 被预测为保守的 miR-33a 靶标,其水平不受 miR-33a 模拟物的下调。在荧光素酶报告基因构建体和 Pim-1 缺陷型 Skov-3 细胞中表达的 Pim-1 cDNA 中对 Pim-1 的 3'-UTR 进行种子突变,表明 miR-33a 模拟物可特异性和直接下调 Pim-1。这种效应的持续时间与小干扰 RNA 介导的 Pim-1 敲低相当,导致细胞增殖速度减慢。总之,我们证明了 miR-33a 作为肿瘤抑制 miRNA 的潜力,这表明通过递送 miR 模拟物进行 miR-33a 替代治疗可能成为一种新的治疗策略。